AIDS 2008 – Mexico City 3-8 August 2008 - XVII Internationnal AIDS Conference

Late Breaker Track B Session 2	THAB04

Organiser:

Type:

Oral Abstract Session

Back

Venue:

SR 1 (6090)

Interpretation:

None

Time:

14:30 - 16:00, 07.08.2008

Code:

THAB04

Co-Chairs:

Pedro Cahn, Argentina
Jose M Gatell, Spain

Click here to see a webcast of this session on kaisernetwork.org

Presentations in this session:

14:30
THAB0401
Abstract
Powerpoint (562 KB) High prevalence of acute HIV infection in Sub-Saharan Africa: a cross sectional, multi-centre screening study
Presented by Francis Martinson, Malawi
G. Kamanga¹, P. Thumbi², M. Nkhoma³, P. Manamela⁴, M. Bogoshi⁵, M. Latka⁵, F. Martinson¹, S.S.A. Karim², J. Kumwenda³, H. Rees⁴, G. Churchyard⁵, M. McCauley⁶, C. Gay⁷, M.S. Cohen⁷
¹University of North Carolina Project, Lilongwe, Malawi, University of North Carolina Project, Kamuzu Central Hospital, Lilongwe, Lilongwe, Malawi, ²CAPRISA, The Centre for AIDS Programme Research in South Africa, Durban, South Africa, ³Johns Hopkins Project, Blantyre, Malawi College of Medicine, Blantyre, Malawi, ⁴RHRU, University of Witwatersrand, Johannesburg, South Africa, ⁵Aurum Health Research, Aurum Health Research, Orkney, South Africa, ⁶Family Health International, Family Health International, Chapel Hill, NC, United States, ⁷University of North Carolina, Chapel Hill, University of North Carolina, Chapel Hill, Chapel Hill, NC, United States

14:45
THAB0402
Abstract
Powerpoint (2.06 MB) IDX899, a novel HIV-1 NNRTI with high barrier to resistance, provides suppression of HIV viral load in treatment-naïve HIV-1-infected subjects
Presented by Carlos Zala, Argentina
C. Zala¹, R. Murphy², X.-J. Zhou³, K. Pietropaolo³, J. Sullivan-Bolyai³, M.-F. Temam⁴, B. Belanger³, D. Mayers³
¹ACLIRES Argentina, Buenos Aires, Argentina, ²Northwestern University Feinberg School of Medicine, Division of Infectious Diseases, Chicago, United States, ³Idenix Pharmaceuticals, Cambridge, United States, ⁴Idenix Pharmaceuticals, Montpellier, France

15:00
THAB0403
Abstract
Powerpoint (1.17 MB) Antiviral activity of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of näive HIV patients
Presented by Graeme Moyle, United Kingdom
G. Moyle¹, M. Boffito¹, K. Manhard², B. Sheedy², V. Hingorani³, L.-T. Yeh², B. Quart²
¹Chelsea and Westminster Hospital, Department of HIV and Genitourinary Medicine, London, United Kingdom, ²Ardea Biosciences, Inc., San Diego, United States, ³Vanguard Healthsciences, Inc, San Diego, United States

15:15
THAB0404
Abstract
Powerpoint (393 KB) PEARLS (ACTG A5175): a multinational study of didanosine-EC, emtricitabine and atazanavir vs. co-formulated zidovudine/lamivudine and efavirenz for initial treatment of HIV-1 infection
Presented by Thomas Campbell, United States
T. Campbell¹, L. Smeaton², V. De Grutolla², J. Hakim³, N. Kumarasamy⁴, T. Flanigan⁵, K. Klingman⁶, A. Martinez⁶, S. Berendes⁷, S. Cardoso⁸, C. Firnhaber⁹, M. Hosseinipour¹⁰, A. Joglekar¹¹, R. Mngqibisa¹², C. Rivière¹³, J. Sanchez¹⁴, B. Santos¹⁵, K. Supparatpinyo¹⁶, A. Nair¹⁷, A. Walawander¹⁷, L. Hosey¹⁸, L. Moran¹⁸, R. Barnett¹⁹, E. Swann⁶, E. Loeschel²⁰, P. Piliero²¹, G. Pakes²², J. Rooney²³, W. Snowden²⁰, G. Thal²⁴, J. Uy²⁴, A. Andrade²⁵, J. Currier²⁶, J. Eron²⁷, S. Eshleman²⁸, S. Fiscus²⁷, R. Gulick²⁹, D. Haas³⁰, S. Hammer³¹, R. Mitsuyasu²⁶, R. Schooley³², PEARLS study team of the ACTG
¹University of Colorado Denver, Denver, United States, ²Harvard School of Public Health, Boston, United States, ³University of Zimbabwe College of Health Sciences, Harare, Zimbabwe, ⁴YRG Centre for AIDS Research & Education, Chennai, India, ⁵Brown Medical School, Providence, United States, ⁶National Institutes of Health, HIV Research Branch, Bethesda, United States, ⁷University of Malawi College of Medicine, Blantyre, Malawi, ⁸Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil, ⁹University of Witwatersrand, Johannesburg, South Africa, ¹⁰Kamuza Central Hospital, Lilongwe, Malawi, ¹¹National AIDS Research Institute, Pune, India, ¹²University of KwaZulu Natal Medical School, Durban, South Africa, ¹³Les Centres GHESKIO, Port-au-Prince, Haiti, ¹⁴IMPACTA PERU Clinical Trials Unit, Lima, Peru, ¹⁵Hospital Nossa Senhora da, Conceicao/GHC, Porto Alegre, Brazil, ¹⁶Chiang Mai University, Chiang Mai, Thailand, ¹⁷Frontier Science & Technology Research Foundation, Buffalo, United States, ¹⁸Social & Scientific Systems, Inc., Silver Spring, United States, ¹⁹National Institutes of Health, Office of Science Policy, Bethesda, United States, ²⁰GlaxoSmithKline, Greenford, United Kingdom, ²¹Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, United States, ²²GlaxoSmithKline, Research Triangle Park, United States, ²³Gilead Sciences, Foster City, United States, ²⁴Bristol-Myers Squibb, Princeton, United States, ²⁵Johns Hopkins University, Baltimore, United States, ²⁶University of California, Los Angeles, Los Angeles, United States, ²⁷University of North Carolina, Chapel Hill, United States, ²⁸Johns Hopkins Medical Institution, Baltimore, United States, ²⁹Weill Medical College of Cornell University, New York, United States, ³⁰Vanderbilt University College of Medicine, Nashville, United States, ³¹Columbia University Medical Center, New York, United States, ³²University of California, San Diego, San Diego, United States

15:30
THAB0405
Abstract A pivotal biostudy comparing ritonavir 100 mg film-coated tablet to a ritonavir 100 mg soft gelatin capsule in healthy adult subjects
Presented by Barry Bernstein, United States
C. Klein¹, Y.-L. Chiu¹, W. Awni¹, W.-K. Ng¹, J. Xiong¹, W. Roth², T. Podsadecki¹, D. Kim¹, B. Bernstein¹
¹Abbott Laboratories, Abbott Park, United States, ²Abbott GmbH, Ludwigshafen, Germany

15:45
THAB0406
Abstract
Powerpoint (696 KB) High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial
Presented by Yazdan Yazdanpanah, France
Y. Yazdanpanah¹, C. Fagard², D. Descamps³, A.M. Taburet⁴, B. Roquebert³, I. Tschope², C. Katlama⁵, G. Pialoux⁶, C. Jacomet⁷, C. Piketty⁸, D. Bollens⁹, J.-M. Molina¹⁰, G. Chene²
¹Tourcoing Hospital, Tourcoing, France, ²INSERM U897, Bordeaux, France, ³Bichat-Claude Bernard Hosp, Paris, France, ⁴Kremlin Bicetre Hosp, Paris, France, ⁵Pitie-Salpetriere Hosp, Paris, France, ⁶Tenon Hosp, Paris, France, ⁷Clermont-Ferrand Hosp, Clermont-Ferrand, France, ⁸Georges Pompidou Hosp, Paris, France, ⁹Saint-Antoine Hosp, Paris, France, ¹⁰Saint-Louis Hosp, Paris, France

Rapporteur report

Track B report by Francois Venter

THAB0401 - High prevalence of acute HIV infection in Sub-Saharan Africa: a cross sectional, multicentre screening study - G. Kamanga, P. Thumbi, M. Nkhoma, P. Manamela, M. Bogoshi, M. Latka, F. Martinson, S.S.A. Karim, J. Kumwenda, H. Rees, G. Churchyard, M. McCauley, C. Gay, M.S. Cohen

Acute HIV has been linked to increased transmission potential, with the added challenge that it is difficult to detect by conventional testing technologies. CHAVI 001 study – to collect and document the demographic, behavioural, clinical, immunological and other characteristics, from 5 sites in SSA. Over 10 000 clients have been screened, with 114 acute infections. 90 subjects were enrolled, with 19 of their partners enrolled (2 have contracted HIV since). Of the 90, equal gender distribution with a mean age of 24 years. 53% had an STI at entry, the majority GUD. Median CD4 was 454, VL 181 000. Lots more data. High prevalence of Ab- neg STD clients. 26% had a discordant results at screening, 2/3 had GUD.

THAB0402 - IDX899, a novel HIV-1 NNRTI with high barrier to resistance, provides suppression of HIV viral load in treatment-naïve HIV-1-infected subjects -
C. Zala, R. Murphy, X.-J. Zhou, K. Pietropaolo, J. Sullivan-Bolyai, M.-F. Temam, B. Belanger, D. Mayers

Phase 2 study. New exciting NNRTI with high barrier to resistance, daily dosing potential. Tested in naïve healthy HIV-positive patients at 3 different doses, for 7 days. Discordance in different VL assays. Excellent antiviral activity and few side effects with all doses.

THAB0403 - Antiviral activity of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor in treatment of näive HIV patients - G. Moyle, M. Boffito, K. Manhard, B. Sheedy, V. Hingorani, L.-T. Yeh, B. Quart

Similar study, also NNRTI. High barrier to resistance (and performs well if K103N is present), good kinetics. Importantly, no animal teratogenicity. Safe and well tolerated over 14 days in healthy volunteers. 7-day efficacy data – also, excellent suppression on all doses, and safe.

THAB0404 - PEARLS (ACTG A5175): a multinational study of didanosine-EC, emtricitabine and atazanavir vs. co-formulated zidovudine/lamivudine and efavirenz for initial treatment of HIV-1 infection - T. Campbell1, Land PEARLS study team

ARV efficacy in developing world contexts were assessed in thsi study. Three different regimens – AZT/3TC with efavirenz, ddI-EC/FTC and ATV daily, TDF/3TC and efav. Over 1 500 patients from low income and rich countries, also different prevalences. DSMB in May 2008 – ATV arm underperformed and was stopped, other two arms still being compared. Median CD4 172, VL 5 logs, 18% prior or current TB.

THAB0405 - A pivotal biostudy comparing ritonavir 100 mg film-coated tablet to a ritonavir 100 mg soft gelatin capsule in healthy adult subjects - C. Klein, Y.-L. Chiu1, W. Awni, W.-K. Ng, J. Xiong, W. Roth, T. Podsadecki, D. Kim, B. Bernstein

Tablet would be easier to store and perhaps easer to take. Swelling of the original tablet – absorbs moisture at room temperature; alternative tablet designed. Bioequivalent data good, similar side effect rates.

THAB0406 - High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial
Y. Yazdanpanah, C. Fagard, D. Descamps, A.M. Taburet, B. Roquebert, I. Tschope, C. Katlama, G. Pialoux, C. Jacomet, C. Piketty, D. Bollens, J.-M. Molina, G. Chene

Very resistant patients, enrolled on above three drugs with OBT, sensitive to etravirine – 101/ 103 patients completed 24 weeks, (median completion of 13 years of ART); at week 24, 90% achived <50 copies /ml (60% at 8 weeks!); 3 patients with VL>400. 2 clinical adverse events, 5 lab events. Ongoing to 96 weeks.

The organizers reserve the right to amend the programme.